Creserol - Flavocure Biotech
Latest Information Update: 28 Mar 2022
At a glance
- Originator Flavocure Biotech
- Class Antineoplastics; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 25 Mar 2022 Preclinical trials in Acute myeloid leukaemia in USA, prior to March 2022 (Flavocure Biotech pipeline, March 2022)
- 25 Mar 2022 Creserol receives Orphan Drug status for Acute myeloid leukaemia in USA, prior to march 2022 (Flavocure Biotech pipeline, March 2022)
- 25 Mar 2022 Flavocure plans a phase I trial in Acute myeloid leukemia (Flavocure Biotech pipeline, March 2022)